<DOC>
	<DOCNO>NCT00493194</DOCNO>
	<brief_summary>This prospective , randomize study , compare sirolimus cyclosporine renal transplant recipient , two major objective : 1 . -To determine incidence degree interstitialfibrosis arteriosclerosis , wel glomerular volume protocol biopsies 6 month sirolimus-and cyclosporine-treated renal allograft recipient , mean quantitative computerized image analysis . - To determine prognostic implication morphologic change . 2 . To study expression gene , involve inflammation fibrosis , protocol biopsy 6 month sirolimus-and cyclosporine-treated renal allograft recipient .</brief_summary>
	<brief_title>Fibrosis Renal Allografts</brief_title>
	<detailed_description>Calcineurin inhibitor significantly improve one-year graft survival renal allograft . However , chronic nephrotoxicity cause calcineurin inhibitor contribute long-term decline renal function kidney transplant recipient . Approximately ninety percent protocol biopsy renal allograft , perform 18 month post transplantation , show histological lesion chronic calcineurin nephrotoxicity . In recent year , two new non-nephrotoxic immunosuppressive drug , i.e . mycophenolate mofetil sirolimus , become available prophylaxis graft rejection renal transplantation . Three randomized clinical trial , compare cyclosporine sirolimus combination mycophenolate mofetil , report superior graft function one year sirolimus treat renal allograft recipient . However , data long-term graft survival histological lesion protocol biopsy sirolimus-treated renal transplant recipient , currently lack . In analogy previous observation native kidney disease , Grimm et al . recently report interstitial fibrosis protocol biopsy renal allograft , 6 month post transplantation , significantly inversely correlate subsequent graft survival One hundred recipient first renal allograft randomize immunosuppressive protocol base cyclosporine ( 50 patient ) sirolimus ( 50 patient ) . Concommittant immunosuppression similar group , consist Daclizumab induction treatment ( five iv gift every two week ) , mycophenolate mophetil steroid maintenance immunosuppression . Randomization perform centre avoid centre-related bias . All patient complete follow-up 12 month . Two core biopsy graft obtain recipient , implantation 6 month . Serum creatinine estimate creatinine clearance ( Nankivell Jellife method ) monthly record .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Recipients renal allograft , minimum age 18 year . 2 . Male female recipient . Women childbearing age must practice adequate contraception 3 . For renal allograft live donor , least one HLAmismatch require . 4 . Written informed consent , compliant local regulation . 1 . Recipients second third renal allograft , past history graft failure due rejection . 2 . Recipients renal allograft haplotypeidentical living donor nonheart beat donor . 3 . Cold ischemia time &gt; 24 hour 4 . Recipients kidney donor ≥ 65 year age 5 . Recipients multiple organ . 6 . Pregnant woman . 7 . Immunological highrisk recipient , define current historical PRA &gt; 50 % 8 . Recipients focal segmental sclerosis primary renal disease . 9 . Recipients leucopenia ( WBC &lt; 3000/mmÂ³ ) , thrombocytopenia ( Thr &lt; 100.000/mmÂ³ ) , hyperlipidemia ( Tot Chol &gt; 300 mg/dl Triglycerides &gt; 300 mg/dl ) 10 . Previous history malignancy , except completely excise basocellular skin tumor 11 . Chronic active infection . 12 . Inadequate compliance treatment . 13 . Use specific drug : Terfenadine , pimozide , astemizole , fluconazole , ketoconazole cimetidine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Cyclosporine toxicity</keyword>
	<keyword>Interstitial Fibrosis</keyword>
	<keyword>Chronic allograft nephropathy</keyword>
	<keyword>Sirolimus</keyword>
</DOC>